<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2021.102007</article-id><article-id pub-id-type="publisher-id">HJO-43136</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20210200000_44696405.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  玻璃体腔内注射曲安奈德治疗慢性顽固性人工晶状体眼黄斑囊样水肿的临床研究
  Clinical Research of Intravitreal Triamcinolone Acetonide for Refractory Chronic Pseudophakic Cystoid Macular Edema
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韦</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>连</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>彦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>廖</surname><given-names>可</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都爱迪眼科医院，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>17</day><month>05</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>64</fpage><lpage>68</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：评价玻璃体腔内注射曲安奈德治疗慢性顽固性人工晶状体眼黄斑囊样水肿的有效性和安全性。方法：非随机回顾性研究白内障术后慢性顽固性人工晶状体眼黄斑囊样水肿(Cystoid Macular Edema, CME)的患者23例23眼。患者CME持续6~10月。所有CME患者接受1 mg曲安奈德玻璃体腔内注射，随访12月。疗效评价指标有最佳矫正视力，裂隙灯显微镜检查，血管渗漏的荧光血管造影及眼压，光学相干断层扫描测量黄斑中心凹视网膜厚度和相关并发症的处理。结果：所有CME患者玻璃体腔注射后视力均有提高；视力提高与治疗前原有视力和是否伴有黄斑病变相关。裂隙灯显微镜检查显示23例患者CME均有好转，治疗后荧光血管造影显示血管渗漏均有减轻。11例出现一过性眼压升高，用降眼压药物均易控制；未见其它并发症。延长随访时间，发现视力有轻度回退且需要再次注射，9例患者分别治疗2～5次，平均间隔时间8周(2.5~24周)。结论：本研究显示玻璃体腔内注射曲安奈德对治疗白内障术后顽固性人工晶状体眼黄斑囊样水肿是安全有效的，可使患者视力显著提高，使CME缓解或消失，治疗痛苦小，但长期随访发现有复发和视力回退，部分患眼需再次注射。研制玻璃体腔内药物缓释系统有利于治疗该病。对于该技术的更确切疗效、安全性、治疗时机和适应证尚需进行前瞻性随机化临床试验。
   Objective: To determine the safety and efficacy of intravitreal triamcinolone acetonide (TAAC) injections in patients with refractory cystoid macular edema (CME) after cataract extraction. Methods: In this nonrandomized retrospective case review, 23 eyes of 23 patients with a history of pseudophakic CME recalcitrant to current standard treatment modalities were enrolled. The mean duration of the CME was 6~10 months. The patients received intravitreal injections of 1 mg of TAAC and were followed for a mean of 12 months. The main outcome measures included visual acuity, the presence of CME on biomicroscopic examination, angiographic evidence of perifoveal leakage, intraocular pressure (IOP), measurement of the optical coherence tomography on central macular thickness (CMT), and complications related to treatment. Results: The visual acuity increased in all patients. The magnitude of improvement was mainly restricted by underlying macular pathology and correlated well with the level of visual acuity at entry into the study. The presence of CME improvement occurred on biomicroscopic examination in all patients, Angiographic improvement occurred in all patients. 11 cases had temporary increases in IOP, which were easily controlled with topical medications. No other adverse effects could be attributed to this technique. Repeated injections were required. After prolonged follow-up, it was found that the visual acuity had a slight regression and needed to be injected again. 9 patients were treated respectively 2~5 times with an average interval of 8 weeks (2.5~24 weeks). Conclusions: Intravitreal administration of TAAC was safe and effective in recalcitrant cases of pseudophakic CME with a beneficial effect on the macular edema and visual acuity. Long-term follow-up found a recurrence and eyesight back. Repeated injections were required in part of all eyes. The development of a sustained- release intravitreal drug-delivery system would be beneficial. A prospective randomized study is needed to determine with accuracy the efficacy, safety, and exact timing of this technique and possibly to recognize subtypes with a more favorable response.
 
</p></abstract><kwd-group><kwd>曲安奈德，人工晶状体眼，黄斑囊样水肿，临床研究, Triamcinolone Acetonide</kwd><kwd> Pseudophakia</kwd><kwd> Cystoid Macular Edema</kwd><kwd> Clinical Research</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价玻璃体腔内注射曲安奈德治疗慢性顽固性人工晶状体眼黄斑囊样水肿的有效性和安全性。方法：非随机回顾性研究白内障术后慢性顽固性人工晶状体眼黄斑囊样水肿(Cystoid Macular Edema, CME)的患者23例23眼。患者CME持续6~10月。所有CME患者接受1 mg曲安奈德玻璃体腔内注射，随访12月。疗效评价指标有最佳矫正视力，裂隙灯显微镜检查，血管渗漏的荧光血管造影及眼压，光学相干断层扫描测量黄斑中心凹视网膜厚度和相关并发症的处理。结果：所有CME患者玻璃体腔注射后视力均有提高；视力提高与治疗前原有视力和是否伴有黄斑病变相关。裂隙灯显微镜检查显示23例患者CME均有好转，治疗后荧光血管造影显示血管渗漏均有减轻。11例出现一过性眼压升高，用降眼压药物均易控制；未见其它并发症。延长随访时间，发现视力有轻度回退且需要再次注射，9例患者分别治疗2～5次，平均间隔时间8周(2.5~24周)。结论：本研究显示玻璃体腔内注射曲安奈德对治疗白内障术后顽固性人工晶状体眼黄斑囊样水肿是安全有效的，可使患者视力显著提高，使CME缓解或消失，治疗痛苦小，但长期随访发现有复发和视力回退，部分患眼需再次注射。研制玻璃体腔内药物缓释系统有利于治疗该病。对于该技术的更确切疗效、安全性、治疗时机和适应证尚需进行前瞻性随机化临床试验。</p></sec><sec id="s2"><title>关键词</title><p>曲安奈德，人工晶状体眼，黄斑囊样水肿，临床研究</p></sec><sec id="s3"><title>Clinical Research of Intravitreal Triamcinolone Acetonide for Refractory Chronic Pseudophakic Cystoid Macular Edema<sup> </sup></title><p>Bin Wei, Hao Lian, Yan Deng, Ke Liao</p><p>Department of Ophthalmology, Cheng Du Aidi Eye Hospital, Chengdu Sichuan</p><p><img src="//html.hanspub.org/file/5-2230333x4_hanspub.png" /></p><p>Received: May 16<sup>th</sup>, 2021; accepted: Jun. 5<sup>th</sup>, 2021; published: Jun. 16<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/5-2230333x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To determine the safety and efficacy of intravitreal triamcinolone acetonide (TAAC) injections in patients with refractory cystoid macular edema (CME) after cataract extraction. Methods: In this nonrandomized retrospective case review, 23 eyes of 23 patients with a history of pseudophakic CME recalcitrant to current standard treatment modalities were enrolled. The mean duration of the CME was 6~10 months. The patients received intravitreal injections of 1 mg of TAAC and were followed for a mean of 12 months. The main outcome measures included visual acuity, the presence of CME on biomicroscopic examination, angiographic evidence of perifoveal leakage, intraocular pressure (IOP), measurement of the optical coherence tomography on central macular thickness (CMT), and complications related to treatment. Results: The visual acuity increased in all patients. The magnitude of improvement was mainly restricted by underlying macular pathology and correlated well with the level of visual acuity at entry into the study. The presence of CME improvement occurred on biomicroscopic examination in all patients, Angiographic improvement occurred in all patients. 11 cases had temporary increases in IOP, which were easily controlled with topical medications. No other adverse effects could be attributed to this technique. Repeated injections were required. After prolonged follow-up, it was found that the visual acuity had a slight regression and needed to be injected again. 9 patients were treated respectively 2~5 times with an average interval of 8 weeks (2.5~24 weeks). Conclusions: Intravitreal administration of TAAC was safe and effective in recalcitrant cases of pseudophakic CME with a beneficial effect on the macular edema and visual acuity. Long-term follow-up found a recurrence and eyesight back. Repeated injections were required in part of all eyes. The development of a sustained-release intravitreal drug-delivery system would be beneficial. A prospective randomized study is needed to determine with accuracy the efficacy, safety, and exact timing of this technique and possibly to recognize subtypes with a more favorable response.</p><p>Keywords:Triamcinolone Acetonide, Pseudophakia, Cystoid Macular Edema, Clinical Research</p><disp-formula id="hanspub.43136-formula26"><graphic xlink:href="//html.hanspub.org/file/5-2230333x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-2230333x7_hanspub.png" /> <img src="//html.hanspub.org/file/5-2230333x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>黄斑囊样水肿(cystoid macular edema, CME)是白内障术后一种常见并发症，其特点是病程长，对矫正视力的影响明显 [<xref ref-type="bibr" rid="hanspub.43136-ref1">1</xref>]。它的发病机制尚未明确，目前认为主要是由于手术本身引起的血–房水屏障破坏释放以前列腺素类为主的炎性介质有关。前列腺类炎性介质能进而破坏血–视网膜屏障，引起黄斑中心凹周围毛细血管的渗漏，导致视网膜层间液体的积聚 [<xref ref-type="bibr" rid="hanspub.43136-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.43136-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43136-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43136-ref5">5</xref>]。白内障术后渗出液主要集中于黄斑部视网膜内颗粒层或和外从状层。黄斑区的Henle纤维呈放射状排列，当液体达一定量时则形成放射状的囊样水肿，即黄斑囊样水肿 [<xref ref-type="bibr" rid="hanspub.43136-ref6">6</xref>]。如何有效地治疗白内障术后的CME，以达到长期维持良好的术后矫正视力，已日益成为临床关注的难题之一。传统的治疗如局部或全身使用糖皮质激素、黄斑区格栅样光凝及手术治疗可能对部分病例有效，但因各自的局限性尚不能被临床广泛接受。近年来，曲安奈德用于治疗各种原因引起的黄斑囊样水肿的研究有了一定的进展，我们对23例白内障术后慢性顽固性人工晶状体眼黄斑囊样水肿的患者进行玻璃体腔注射曲安奈德，取得了良好的效果，现总结报告如下。</p></sec><sec id="s6"><title>2. 对象与方法</title><p>1、对象：选取自2017年7月以来收治的白内障术后慢性顽固性人工晶状体眼黄斑囊样水肿的患者23例23眼，其中男12例12眼，女11例11眼；年龄43~78岁，平均(60.35 &#177; 7.52)岁；19例19眼患者曾行白内障超声乳化摘除联合人工晶体植入术；4例4眼患者曾行白内障现代囊外摘除联合人工晶体植入术。诊断依据：眼底检查可见黄斑水肿，呈囊样改变，持续时间为6~10月，平均8月。早期治疗包括局部及全身应用糖皮质激素、非甾体类抗炎药等，患者视力及水肿无明显改善。所有病例治疗前行眼部详细检查，包括最佳矫正视力、眼压、前置镜检查眼底，眼底荧光血管造影，光学相干断层扫描测量黄斑中心凹视网膜厚度(central macular thickness, CMT)等。</p><p>2、手术方法：所有操作均在手术室无菌条件下进行。0.5%盐酸丙美卡因表面麻醉，常规消毒、铺巾，开睑器开睑，在颞上方距角巩膜缘约3.8 mm处的睫状体平坦部垂直巩膜面穿刺入玻璃体腔，缓慢抽取0.1 ml玻璃体，将曲安奈德注射液(Italy LISAPHARMA生产，规格：每支40 mg/m1)直接抽取0.05 ml，用0.9%生理盐水稀释至0.1 ml (10 mg/m1)，拔出抽有玻璃体的针管，将装有曲安奈德的针管接到穿入玻璃体腔的针头上，在颞上方由睫状体平坦部垂直巩膜面进针约10 mm，将药推入，拔出针头，湿棉签按压注射部位1 min。涂抗生素眼膏，包扎术眼。以上操作均由同一位熟练医师完成。</p><p>3、疗效评价：治疗后1周、1月、3月、6月、12月分别检查最佳矫正视力，眼压，裂隙灯显微镜检查，血管渗漏的荧光血管造影及光学相干断层扫描测量黄斑中心凹视网膜厚度和治疗的相关并发症。</p><p>4、统计学方法：采用计算机SPSS19.0统计软件分析，数据均以( X &#175; &#177; s )表示。统计学方法：治疗前后比较采用独立样本的t检验，P &lt; 0.05认为有统计学意义。</p></sec><sec id="s7"><title>3. 结果</title><p>1、视力恢复情况：经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者，其治疗后1周、1月、3月、6月、12月的视力均较治疗前有明显的提高，差异具有统计学意义(P &lt; 0.05)；随访后期发现视力略有回落，但仍较治疗前有明显的提高，差异具有统计学意义(P &lt; 0.05)；随访期间视力变化差异无统计学意义(P &gt; 0.05)。结果见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Visual acuity, intraocular pressure and CMT of 23 patients with chronic intractable intraocular lens cystoid macular edema after intravitreal injection of triamcinolone acetonide ( X &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >视力</th><th align="center" valign="middle" >眼压mmHg</th><th align="center" valign="middle" >CMTμm</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >4.38 &#177; 0.23</td><td align="center" valign="middle" >15 &#177; 1.41</td><td align="center" valign="middle" >541.73 &#177; 83.15</td></tr><tr><td align="center" valign="middle" >治疗后1周</td><td align="center" valign="middle" >4.63 &#177; 0.19<sup>※ </sup></td><td align="center" valign="middle" >29 &#177; 1.23<sup>※ </sup></td><td align="center" valign="middle" >287.20 &#177; 63.38<sup>※</sup></td></tr><tr><td align="center" valign="middle" >治疗后1月</td><td align="center" valign="middle" >4.63 &#177; 0.26<sup>※ </sup></td><td align="center" valign="middle" >19 &#177; 1.35</td><td align="center" valign="middle" >281.75 &#177; 104.12<sup>※</sup></td></tr><tr><td align="center" valign="middle" >治疗后3月</td><td align="center" valign="middle" >4.64 &#177; 0.17<sup>※ </sup></td><td align="center" valign="middle" >18 &#177; 1.27</td><td align="center" valign="middle" >273.62 &#177; 77.23<sup>※</sup></td></tr><tr><td align="center" valign="middle" >治疗后6月</td><td align="center" valign="middle" >4.57 &#177; 0.21<sup>※ </sup></td><td align="center" valign="middle" >17 &#177; 1.31</td><td align="center" valign="middle" >312.15 &#177; 89.12<sup>※</sup></td></tr><tr><td align="center" valign="middle" >治疗后12月</td><td align="center" valign="middle" >4.56 &#177; 0.24<sup>※ </sup></td><td align="center" valign="middle" >17 &#177; 1.29</td><td align="center" valign="middle" >309.07 &#177; 96.28<sup>※</sup></td></tr></tbody></table></table-wrap><p>表1. 经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者治疗前后视力，眼压及CMT比较( X &#175; &#177; s )</p><p><sup>※</sup>P &lt; 0.05.</p><p>2、黄斑中心凹视网膜厚度：经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者，其治疗后1周、1月、3月、6月、12月的黄斑水肿均较治疗前有明显的消退，黄斑中心凹视网膜厚度较治疗前有明显变薄。差异具有统计学意义(P &lt; 0.05)；随访期间黄斑水肿消退差异无统计学意义(P &gt; 0.05)。结果见表1。</p><p>3、眼底改变：治疗前23例研究对象的眼底荧光血管造影显示存在不同程度的黄斑水肿，黄斑花瓣样渗漏。治疗后眼底荧光血管造影显示黄斑水肿明显消退，黄斑花瓣样渗漏明显减轻或大部消失。</p><p>4、黄斑水肿复发情况：23例患者中有9例患者存在黄斑水肿复发的情况，复发率为39.1%，需要再次行玻璃体腔注射曲安奈德。</p><p>5、并发症：1) 术后高眼压：经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者中有11例在治疗后1周出现一过性高眼压(眼压 &gt; 21 mm Hg，1 mm Hg = 0.133 kPa)，高眼压发生率为47.8%，较治疗前差异有统计学意义(P &lt;0.05)，用降眼压药物均易控制。以后随访期间的眼压情况差异无统计学意义(P &gt; 0.05)。结果见表1。2) 其他并发症：3眼发生注射处结膜下出血。所有治疗眼均无视网膜脱离，玻璃体积血及感染性眼内炎等严重并发症发生。</p></sec><sec id="s8"><title>4. 讨论</title><p>白内障术后黄斑囊样水肿又称为Irvine-Gass综合征，常发生于白内障术后4~12周。白内障术后黄斑囊样水肿的发生原因尚不明确，可能与手术期间血–视网膜屏障的破坏及机械牵拉等因素有关。白内障术后慢性顽固性黄斑水肿是指水肿持续存在超过6月，并影响患者中心视力。黄斑囊样水肿时间越长，其自行消退的可能性就越小，可能会损害光感受器及色素上皮功能，继发浆液性视网膜脱离，形成视网膜前膜，甚至发展为黄斑部板层裂孔，对患眼的中心视力产生严重威胁，目前，临床上常用的药物、激光和手术等各种方法来治疗黄斑水肿，但均具有其局限性。本研究注意到：曲安奈德作为一种人工合成的含氟长效糖皮质激素，近年被用来治疗糖尿病性视网膜病变、视网膜中央静脉阻塞等引起的难治性黄斑囊样水肿，取得了满意的效果 [<xref ref-type="bibr" rid="hanspub.43136-ref7">7</xref>]。分析其主要的作用机制为抑制或减少炎症因子(白细胞、前列腺素等)的产生和释放，从而有维护血–视网膜屏障的作用。同时本研究将曲安奈德直接注射入玻璃体腔内，将药物直接作用于靶部位，使曲安奈德在玻璃体腔内维持较高的药物浓度，减轻黄斑炎症反应，并最大限度地减少了激索导致全身副作用的发生，有利于充分发挥曲安奈德的生物活性，减轻血–视网膜屏障破坏的程度 [<xref ref-type="bibr" rid="hanspub.43136-ref8">8</xref>]。通过我们的研究发现玻璃体腔注射曲安奈德后，患者的视力较治疗前有明显的提高，黄斑区中心凹视网膜厚度与注射前相比明显降低。</p><p>本研究还考虑到：眼底荧光血管造影虽是诊断黄斑囊样水肿必不可少的手段，是传统诊断黄斑囊样水肿的“金标准”。但眼底荧光血管造影只观察到黄斑区荧光素的渗漏程度，却无法观察到黄斑区视网膜的增厚程度。而近年来有学者提出白内障术后视网膜内屏障破坏，血浆从黄斑周围的视网膜毛细血管渗入到组织中，形成局部病灶或弥漫性黄斑水肿，真正引起视力下降不是黄斑区血管的渗漏程度。而是黄斑视网膜增厚的程度，白内障术后慢性顽固性黄斑水肿才是引起中心视力下降的重要原因 [<xref ref-type="bibr" rid="hanspub.43136-ref9">9</xref>]。因此，我们的研究采用光学相干断层扫描随访监测黄斑中心凹视网膜厚度的变化就显得尤为重要。根据我们的研究发现经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者，其治疗后1周、1月、3月、6月、12月的黄斑水肿均较治疗前有明显的消退，黄斑中心凹视网膜厚度较治疗前有明显变薄。差异具有统计学意义(P &lt; 0.05)；随访期间黄斑水肿消退差异无统计学意义(P &gt; 0.05)。经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者在治疗前眼底荧光血管造影显示存在不同程度的黄斑水肿，黄斑花瓣样渗漏。治疗后眼底荧光血管造影显示黄斑水肿明显消退，黄斑花瓣样渗漏明显减轻或大部消失。但我们也发现玻璃体腔注射曲安奈德早期能促进视网膜水肿吸收，提高视力疗效明显，长期随访则有复发和视力回退的现象，表现为随访后期黄斑中心凹视网膜厚度略有增加，但差异无统计学意义(P &gt; 0.05)。本研究中有9例患者存在黄斑水肿复发的情况，复发率为39.1%，需要再次行玻璃体腔注射曲安奈德。</p><p>经玻璃体腔注射曲安奈德的慢性顽固性人工晶状体眼黄斑囊样水肿的23例患者中有11例在治疗后1周出现一过性高眼压，高眼压发生率为47.8%，较治疗前差异有统计学意义(P &lt; 0.05)，用降眼压药物均易控制。以后随访期间的眼压情况差异无统计学意义(P &gt; 0.05)。所有眼压升高的患者除轻微眼胀外均无明显的眼痛、头痛及恶心等高眼压症状，并且大多数患者经1~2 h后眼压均可自行恢复至正常范围。少数高眼压患者也不需全身用药一般局部应用降眼压药物治疗眼压均可恢复至正常范围。但我们认为玻璃体腔内注射曲安奈德引起眼压升高是一个潜在的危险因素，应引起医生和患者的重视。因此，患者定期随诊测量眼压非常必要。此外，我们认为，术后眼压升高似乎与重复注射药物，即眼内药物的浓度和维持时间没有明显相关性，可能是与糖皮质激素性青光眼相应的靶基因有关 [<xref ref-type="bibr" rid="hanspub.43136-ref10">10</xref>]。本研究中有3例发生注射处结膜下出血，未发生感染性眼内炎，玻璃体腔出血、视网膜脱离等严重并发症。</p><p>总之，玻璃体腔内注射曲安奈德对白内障术后慢性黄斑囊样水肿是一种安全、有效的治疗方法。对于注射后复发病例，尚有待于进一步研究其原因及再次治疗的方法。对于该技术的确切疗效、安全性、治疗时机和适应证尚需进行前瞻性随机化临床试验，以寻求治疗黄斑囊样水肿的最佳方案。我们认为研制玻璃体腔内药物缓释系统将有利于治疗该病。由于本研究例数有限，并且没有对照组，缺乏对远期效果的分析。还需大样本、多中心、长时间的对照研究来进一步确定疗效。</p></sec><sec id="s9"><title>作者申明</title><p>该研究获得医学伦理委员会审核批准。</p></sec><sec id="s10"><title>文章引用</title><p>韦 斌,连 浩,邓 彦,廖 可. 玻璃体腔内注射曲安奈德治疗慢性顽固性人工晶状体眼黄斑囊样水肿的临床研究Clinical Research of Intravitreal Triamcinolone Acetonide for Refractory Chronic Pseudophakic Cystoid Macular Edema[J]. 眼科学, 2021, 10(02): 64-68. https://doi.org/10.12677/HJO.2021.102007</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43136-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">尹澜, 皮裕蜊. 糖尿病与白内障术后出现黄斑囊样水肿相关性的临床分析[J]. 国际眼科杂志, 2007, 7(3): 816-817.</mixed-citation></ref><ref id="hanspub.43136-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sivaprasad, S., Bunce, C. and Patel, N. (2005) Non-Steroidal Anti-Inflammatory Agents for Treating Cystoid Macular Oedema following Cataract Surgery. Cochrane Database of Systematic Reviews Review, 25, 39-42.</mixed-citation></ref><ref id="hanspub.43136-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, T.P. (2005) Emerging Guidelines for Use of NSAID Therapy to Optimize Cataract Surgery Patient Care. Current Medical Research and Opinion, 21, 1131-1137. https://doi.org/10.1185/030079905X50651</mixed-citation></ref><ref id="hanspub.43136-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Flach, A.J. (1998) The Incidence, Pathogenesis and Treatment of Cystoids Macular Edema Following Cataract Surgery. Trans Am Ophthalmol Soc, 96, 557-634.</mixed-citation></ref><ref id="hanspub.43136-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rossetti, L., Chandhuri, J. and Dickersin, K. (1998) Medical Prophylaxis and Treatment of Cystoid Macular Edema after Cataract Surgery. The Results of a Ameta-Analysis. Ophthalmology, 105, 397-405.  
https://doi.org/10.1016/S0161-6420(98)93018-4</mixed-citation></ref><ref id="hanspub.43136-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">谢茂松, 徐围兴. Irvine——Gass综合征的发病机制[J]. 国际眼科纵览, 2007, 31(3): 183-185.</mixed-citation></ref><ref id="hanspub.43136-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jonas, J.B., Kreissig, I. and Sofker, A. (2003) Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema. Arch Ophthalmol, 121, 57-61. https://doi.org/10.1001/archopht.121.1.57</mixed-citation></ref><ref id="hanspub.43136-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘谊, 严密. 曲安奈德玻璃体腔注射的临床应用[J]. 中华眼底病杂志, 2003, 19(4): 263-265.</mixed-citation></ref><ref id="hanspub.43136-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, M.W. (2009) Etiology and Treatment of Macuiar Edema. American Journal of Ophthalmology, 147, 11-21.  
https://doi.org/10.1016/j.ajo.2008.07.024</mixed-citation></ref><ref id="hanspub.43136-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">刘铁城, 王炜, 金鑫, 等. 玻璃体内注射曲安奈德治疗视网膜中央静脉阻塞引起的黄斑囊样水肿[J]. 中华眼底病杂志, 2005, 21(7): 213-216.</mixed-citation></ref></ref-list></back></article>